TY - JOUR
T1 - Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders
AU - Michel, Martin C.
AU - Cardozo, Linda
AU - Chermansky, Christopher J.
AU - Cruz, Francisco
AU - Igawa, Yasuhiko
AU - Lee, Kyu Sung
AU - Sahai, Arun
AU - Wein, Alan J.
AU - Andersson, Karl Erik
N1 - Publisher Copyright:
© 2023, American Society for Pharmacology and Experimental Therapy (ASPET). All rights reserved.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Overactive bladder syndrome with and without urinary incontinence and related conditions, signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract dysfunction, underactive bladder, stress urinary incontinence, and nocturia are common in the general population and have amajor impact on the quality of life of the affected patients and their partners. Based on the deliberations of the subcommittee on pharmacological treatments of the 7th International Consultation on Incontinence, we present a comprehensive review of established drug targets in the treatment of overactive bladder syndrome and the aforementioned related conditions and the approved drugs used in its treatment. Investigational drug targets and compounds are also reviewed.We conclude that, despite a range of available medical treatment options, a considerable medical need continues to exist. This is largely because the existing treatments are symptomatic and have limited efficacy and/or tolerability, which leads to poor long-termadherence. Significance Statement——Urinary incontinence and related disorders are prevalent in the general population. Whilemany treatments have been approved, few patients stay on long-term treatment despite none of them being curative. This paper provides a comprehensive discussion of existing and emerging treatment options for various types of incontinence and related disorders.
AB - Overactive bladder syndrome with and without urinary incontinence and related conditions, signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract dysfunction, underactive bladder, stress urinary incontinence, and nocturia are common in the general population and have amajor impact on the quality of life of the affected patients and their partners. Based on the deliberations of the subcommittee on pharmacological treatments of the 7th International Consultation on Incontinence, we present a comprehensive review of established drug targets in the treatment of overactive bladder syndrome and the aforementioned related conditions and the approved drugs used in its treatment. Investigational drug targets and compounds are also reviewed.We conclude that, despite a range of available medical treatment options, a considerable medical need continues to exist. This is largely because the existing treatments are symptomatic and have limited efficacy and/or tolerability, which leads to poor long-termadherence. Significance Statement——Urinary incontinence and related disorders are prevalent in the general population. Whilemany treatments have been approved, few patients stay on long-term treatment despite none of them being curative. This paper provides a comprehensive discussion of existing and emerging treatment options for various types of incontinence and related disorders.
UR - https://www.scopus.com/pages/publications/85163750664
U2 - 10.1124/pharmrev.121.000523
DO - 10.1124/pharmrev.121.000523
M3 - Article
C2 - 36918261
AN - SCOPUS:85163750664
SN - 0031-6997
VL - 75
SP - 554
EP - 674
JO - Pharmacological Reviews
JF - Pharmacological Reviews
IS - 4
ER -